Full-Time

Associate Director

Late-Stage Development

Updated on 8/22/2026

Vertex Pharmaceuticals

Vertex Pharmaceuticals

5,001-10,000 employees

Develops therapies for serious genetic diseases

Compensation Overview

$155.7k - $233.5k/yr

+ Annual bonus + Annual equity awards

Company Does Not Provide H1B Sponsorship

Boston, MA, USA

Hybrid

Hybrid work is available up to two remote days per week, or the role may be designated fully on-site.

Bachelor's

Category
Biology & Biotech (1)
Required Skills
Risk Management

Get referred to Vertex Pharmaceuticals

See people who can refer or advise you

Requirements
  • A bachelor's degree in a scientific discipline or related field.
  • Typically 10+ years of relevant experience in the pharmaceutical, biotechnology, or life sciences industry, or an equivalent combination of education and experience.
  • Demonstrated experience in program management supporting nonclinical drug development programs.
  • Experience supporting regulatory submission execution across multiple stages of development, including NDA/BLA submissions and other marketing application activities.
  • Broad and comprehensive knowledge of Good Laboratory Practice regulations.
  • Comprehensive understanding of pharmaceutical drug discovery and development across multiple nonclinical disciplines, including toxicology, drug metabolism and pharmacokinetics, biomarkers, translational sciences, and related functions.
  • Strong understanding of nonclinical regulatory documentation, submission processes, and regulatory milestones across the product lifecycle.
  • Experience coordinating cross-functional authoring, review, approval, and delivery of regulatory submission documentation.
  • Demonstrated ability to manage complex regulatory and development timelines across matrixed teams.
  • Experience driving submission readiness activities and coordinating cross-functional deliverables for major regulatory milestones.
  • Excellent written, verbal, and presentation communication skills.
  • Ability to influence decisions and drive outcomes across multidisciplinary teams.
  • Strong understanding of functions and disciplines outside of one's own area of expertise.
  • Strong organizational, planning, problem-solving, and risk management capabilities.
Responsibilities
  • Establish project team operating norms and drive team effectiveness, accountability, and execution excellence.
  • Independently lead cross-functional teams supporting critical development programs.
  • Develop, maintain, and communicate integrated project plans that align functional deliverables with program objectives and timelines.
  • Review and consolidate project plans, budgets, and resource forecasts; support scenario planning and evaluation of alternative development strategies, including associated risks and assumptions.
  • Partner directly with contract research organizations and external collaborators on the scheduling, execution, and reporting of key preclinical deliverables.
  • Communicate program progress, timeline updates, risks, mitigation strategies, and opportunities to project teams and senior leadership.
  • Track high-level program deliverables and proactively identify operational practices and technologies that improve execution.
  • Forecast and manage program budgets, including oversight of programs managed by direct reports.
  • May serve as study representative for nonclinical studies.
  • Manage one or more direct reports, including professional development, performance management, and goal setting.
  • Lead the planning, tracking, and execution of nonclinical deliverables supporting NDA/BLA marketing applications, IND/CTA applications, supplemental filings, global submissions, and post-marketing regulatory commitments.
  • Serve as the primary operational lead for nonclinical activities supporting marketing application submissions, including submission planning, document coordination, health authority response management, approval readiness, and post-marketing commitment execution.
  • Partner closely with Regulatory Affairs and nonclinical subject matter experts to facilitate authoring, review, approval, and document readiness activities for regulatory submission packages, ensuring alignment across functional contributors.
  • Develop and maintain integrated submission timelines, identifying critical dependencies, risks, and mitigation plans to ensure successful execution of regulatory milestones.
  • Coordinate cross-functional activities supporting initial submissions, follow-on submissions, amendments, supplements, annual reports, and lifecycle management activities.
  • Support preparation and tracking of responses to regulatory agency questions, information requests, and post-submission commitments in collaboration with Regulatory Affairs and functional experts.
  • Ensure submission-related decisions, deliverables, timelines, and action items are appropriately tracked, communicated, and escalated when needed.
  • Support global regulatory submission activities and facilitate alignment across regional and functional stakeholders to enable successful filings.
Desired Qualifications
  • Significant experience supporting nonclinical deliverables for NDA/BLA marketing applications and post-approval regulatory activities; experience with IND/CTA submissions is expected, but late-stage development and filing experience is strongly preferred.
  • Experience coordinating health authority response activities and post-marketing regulatory commitments in partnership with Regulatory Affairs and functional subject matter experts.
  • Experience supporting global regulatory submissions across multiple regions, including the Food and Drug Administration, European Medicines Agency, Medicines and Healthcare products Regulatory Agency, Pharmaceuticals and Medical Devices Agency, and other international health authorities.
  • Knowledge of, or experience working within, an outsourced nonclinical development model.
  • Experience utilizing project management tools and processes to support complex cross-functional development programs.
Vertex Pharmaceuticals

Vertex Pharmaceuticals

View

Vertex Pharmaceuticals develops medicines for serious diseases, with a focus on cystic fibrosis. It conducts extensive research and partners with other biotech firms to discover and develop new therapies, including ex vivo engineered cell treatments. Its products, such as ivacaftor, treat cystic fibrosis and other therapies undergo clinical testing to expand the pipeline. Revenue comes from selling approved drugs and from licensing and collaboration agreements. The company distinguishes itself through deep R&D investment, strategic partnerships, and a global reach aimed at addressing unmet medical needs. The overall goal is to bring effective new drugs to patients worldwide and improve outcomes and quality of life.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1989

Get referred to Vertex Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Vertex raised 2026 revenue guidance to $13.1-$13.2 billion after Q2 growth.
  • Povetacicept has a November 30, 2026 PDUFA date, opening nephrology revenue.
  • JOURNAVX hit $50 million in Q2 2026, while CASGEVY grew 151% year over year.

What critics are saying

  • Sionna axed SION-719 on August 10, 2026, but CF competition keeps advancing.
  • Zimislecel faced a voluntary manufacturing pause in 2026, exposing cell-therapy execution risk.
  • Crinetics adds $8.8 billion integration risk; a failed close leaves Vertex overdependent on CF.

What makes Vertex Pharmaceuticals unique

  • Vertex still owns CFTR modulators; Q2 2026 CF revenue reached $3.2 billion.
  • Vertex broadened beyond CF with CASGEVY, JOURNAVX, and Crinetics, announced July 2026.
  • Vertex moves fast: CASGEVY pediatric FDA approval arrived 53 days after filing.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

8%

1 year growth

8%

2 year growth

8%
Ticker Report
Aug 19th, 2026
Wealthfront Advisers LLC Makes New $20.67 Million Investment in Vertex Pharmaceuticals Incorporated $VRTX

Wealthfront Advisers LLC acquired a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 41,608 shares of the pharmaceutical company’s stock, valued at approximately $20,668,000. Other hedge funds also recently […]

Yahoo Finance
Aug 14th, 2026
Vertex Pharmaceuticals hits all-time high despite CF competition risks

Vertex Pharmaceuticals recently hit an all-time high after bouncing back from recent setbacks. The biotech continues dominating the cystic fibrosis (CF) market with no meaningful competition, generating $3.2 billion in CF revenue last quarter. Second-quarter sales reached $3.33 billion, up 12% year-over-year, whilst earnings per share rose 8% to $4.31. Several competitors have attempted to challenge Vertex's CF dominance, but most have failed. Sionna Therapeutics' leading CF candidate recently flopped in mid-stage trials, whilst AbbVie previously abandoned its CF programmes. Beyond CF, Vertex is expanding into new areas. The company expects $500 million in non-CF revenue by 2026. Its gene editing treatment Casgevy recently earned approval for children as young as two, whilst non-opioid pain medicine Journavx could gain additional indications.

Yahoo Finance
Aug 12th, 2026
Vertex Pharmaceuticals beats Q2 revenue estimates with $3.33B, driven by CF portfolio and newer products

Vertex Pharmaceuticals reported strong second-quarter results, with revenue of $3.33 billion beating analyst estimates of $3.19 billion. The company attributed growth to its cystic fibrosis portfolio and newer products like CASGEVY and JOURNAVX. CEO Reshma Kewalramani highlighted that ALYFTREK and TRIKAFTA continued to drive CF revenue, whilst European launches benefitted from fewer monitoring requirements. The company raised its full-year revenue guidance to $13.15 billion at the midpoint from $13.03 billion. Adjusted earnings per share came in at $4.73, in line with analyst expectations of $4.75. Adjusted operating income reached $1.42 billion, exceeding estimates of $1.37 billion with a 42.7% margin. During the earnings call, analysts questioned management about Phase II/III study doses, payer dynamics for JOURNAVX, and clinical outcomes for next-generation CF therapies.

Yahoo Finance
Aug 11th, 2026
Vertex Q2 2026 revenue up 12% year-on-year, announces Crinetics acquisition

Vertex Pharmaceuticals reported strong second quarter 2026 results during its earnings call on 3 August. The company's total revenue grew 12% year-on-year, driven by its cystic fibrosis portfolio and newer products CASGEVY and JOURNAVX. CEO Dr Reshma Kewalramani highlighted excellent performance across the company's commercial portfolio and research pipeline. Vertex also announced a definitive agreement to acquire Crinetics Pharmaceuticals, which will add rare endocrine diseases as a fifth therapeutic area alongside cystic fibrosis, sickle cell disease, beta-thalassemia, and pain management. The company emphasised 2026 as a year focused on execution across commercial, clinical, and regulatory fronts, with significant progress made during the quarter.

Yahoo Finance
Aug 7th, 2026
Sionna Therapeutics challenges Vertex Pharmaceuticals' $12B cystic fibrosis market dominance

Sionna Therapeutics is challenging Vertex Pharmaceuticals' dominance in the cystic fibrosis (CF) drug market. Vertex, valued at nearly $123 billion, generated $3.2 billion in CF-related sales in Q2, representing most of its $3.33 billion total revenue. Sionna, worth $2.2 billion, claims its approach could restore normal function to the CFTR protein, which causes CF when misfolded. Vertex's current treatments improve the protein's shape and function but don't restore normal function for most patients. Vertex generates over $12 billion annually from CF treatments. However, several companies, including AbbVie, have previously attempted to challenge Vertex's market position without success. Vertex has maintained its position since receiving its first CF drug approval in 2012.